Sirtex Medical Limited shares fall as it gives market update

Is Sirtex Medical Limited (ASX:SRX) cheap or a value trap?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sirtex Medical Limited (ASX: SRX) share price fell this afternoon, despite the liver cancer treatment specialist announcing the appointment of Mr. Andrew McLean as its new chief executive officer.

McLean apparently comes from a senior management role at NYSE-listed STERIS Corporation and has a big task on his hands to reverse the fortunes of a business that has suffered a series of setbacks recently.

The biggest setback was the need to sack its prior CEO after an investigation by legal advisers appointed by the company to look into the circumstances around the prior CEO's share selling.

The company is now subject to an external legal claim for compensation over having allegedly misled the market as to its dose sales guidance and is currently prevented from executing a share buyback as a result of the claim from a Melbourne-based firm of lawyers acting on behalf of one or more aggrieved shareholders.

Resolving the mess left behind by his predecessor will be near the top of the new CEO's agenda then, with the business also missing a Head of Americas after the last incumbent was acknowledged to have been let go by the company on its most recent clinical trials conference call.

Notably, the Head of Americas (before last) left the business on June 30 2016, with sales in this absolutely critical region slowing and the business now searching for its third chief in the region in around 11 months.

The company has also suffered a disappointing set of results for its flagship trials designed to promote the efficacy of its SIR-Spheres treatment for different types of cancer and the new CEO has a lot on his plate to get the business back on track.

Despite the big recent falls in the share price to $11.81 today, I'm not a buyer of Sirtex shares as I remain of the belief that its best days are most likely behind it.

Motley Fool contributor Tom Richardson has no position in any stocks mentioned. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »